Category: type 2

Over at Scientific American, Laura Newman has a post recapping three recent papers in the BMJ that conclude that insulin analogues--genetically engineered insulin replacements--show no compelling advantages over human insulin but cost two to four times as much.

We've heard this kind of story before, but it's worth remembering that despite outsiders' attempts to uncover and discourage such things, the pharmaceutical industry continues, in at least some circumstances, to value marketing over research. And that is precisely where reporters should go to make the distinction and to clarify what's going on--which is what Newman does here.

-Paul Raeburn